Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 28, 2016
SALT LAKE CITY, March 28, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for LPCN 1021, an oral testosterone...
-
Mar 10, 2016
SALT LAKE CITY, March 10, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the full year ended December 31, 2015....
-
Mar 8, 2016
SALT LAKE CITY, March 08, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown,...
-
Feb 27, 2016
SALT LAKE CITY, March 28, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for LPCN 1021, an oral testosterone...
-
Feb 16, 2016Relevant hydroxyprogesterone caproate levels achieved following oral administration
SALT LAKE CITY, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced top-line results from its multi-dose pharmacokinetic ("PK") dose...
-
Jan 4, 2016
SALT LAKE CITY, Jan. 04, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the first patient has been dosed in its Phase 2b clinical...
-
Dec 6, 2015
SALT LAKE CITY, May 18, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the appointment of Jyrki Mattila, M.D., Ph.D., M.B.A to the newly...
-
Nov 23, 2015
SALT LAKE CITY, Nov. 24, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive...
-
Nov 13, 2015
SALT LAKE CITY, Nov. 13, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that on November 12, 2015 its board of directors adopted a...
-
Nov 12, 2015
SALT LAKE CITY, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has assigned a...
-
Nov 11, 2015
SALT LAKE CITY, Nov. 11, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for LPCN 1021, an oral testosterone product...
-
Oct 29, 2015
SALT LAKE CITY, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has accepted...
-
Oct 12, 2015
SALT LAKE CITY, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended September 30, 2015, as...
-
Sep 28, 2015
SALT LAKE CITY, Sept. 28, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the first subject dosed in its multi-dose PK dose finding...
-
Sep 22, 2015
SALT LAKE CITY, Sept. 22, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown,...
-
Aug 31, 2015
SALT LAKE CITY, Aug. 31, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that it has submitted a 505(b)(2) New Drug Application ("NDA") to the
-
Aug 10, 2015
SALT LAKE CITY, Aug. 11, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended June 30, 2015, as well as...
-
Aug 5, 2015
SALT LAKE CITY, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive...
-
Jun 29, 2015LPCN 1021 was well tolerated during 52 weeks of dosing
SALT LAKE CITY, June 29, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced top-line 52-week safety results from its Study of Oral Androgen...
-
Jun 15, 2015
SALT LAKE CITY, June 16, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc.(Nasdaq:LPCN), a specialty pharmaceutical company, today announced today announced Mahesh Patel, President and CEO, and Morgan Brown,...
-
Jun 8, 2015
SALT LAKE CITY, June 8, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced its development plans for LPCN 1107, the company's oral...
-
Jun 2, 2015
SALT LAKE CITY, June 2, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the U.S. Food and Drug Administration ("FDA") has granted orphan...
-
May 11, 2015
SALT LAKE CITY, May 11, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that additional data from its ongoing Study of Oral Androgen...
-
May 7, 2015
SALT LAKE CITY, May 7, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended March 31, 2015, as well as...
-
Apr 30, 2015
SALT LAKE CITY, April 30, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the completion of the last patient visit in the safety...